If you have been reading about visceral adiposity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
The establishment is a modern, structured research institute composed of six laboratories dedicated to Virology, Parasitology, Bacteriology, Medical Entomology, Clinical Biology and Pathology, including a Research Center for animals and a data center. Each laboratory is made up of a dedicated director and staff, including students and international collaborators. Each laboratory has the basic equipment and the space necessary for optimal research. It is available to faculty, students, post-docs and staff from the periphery of the INRB. Due to the structure of the INRB, if sharing and access to individual laboratory equipment is required, access is granted at the request and approval of the directors of these laboratories. The INRB common area includes some major equipment. All collaborators and researchers have, upon request, access to several -80 freezers, liquid nitrogen tanks, centrifuges, water baths, tissue homogenizers, vortexes, incubators, agitators, and all laboratories have access to cold chain equipment such as dry shippers and portable freezers. The INRB was founded in 1984 and has been a World Health Organization collaborating centre since 2018. The INRB and the World Health Organization have worked closely together on research into the effectiveness of the ring vaccination strategy during the 2018 Kivu Ebola outbreak. The National Biomedical Research Institute (INRB) has eight dynamic departments, which participate in the institute's various missions, namely monitoring, research, and training.
The Patrol Ration Pac (PRP) is a shelf-stable product that provides an efficient, flexible and nutritionally robust feeding method. The PRP is designed to cover activities when you have access to other food sources during the day and is ideal to replace a single meal or provide snack options. The PRP provides approximately one-third of the energy and nutrient requirements of most military personnel during moderate, prolonged-intensity physical activity, in a temperate environment. Therefore, it is desirable that all of the food in the pack is eaten. Menus A, B and C contain main meals that can be heated using a flameless ration heater along with other ready to eat foods and a beverage powder. Menu D provides ready to eat snack foods and no beverage powder.
Lewandowski that he ought to realise that his position here was a delicate one... and I added it was highly desirable that his office should not be situated in a building with the Bureau of Polish propaganda". Undercover and illicit activities also started as early as 11 March 1920, when the Earl of Derby reported a decision of the Allied Council of Ambassadors in Paris to make representations to the Polish government regarding the violations of the frontiers of the Marienwerder Plebiscite Area towards Germans by Polish soldiers. Beaumont reported from Marienwerder at the end of March that "no change has been made in the methods of Polish propaganda. Occasional meetings are held, but they are attended only by Poles in small numbers". He continued to note that "acts and articles violently abusive of everything German in the newly founded Polish newspaper appear to be the only (peaceful) methods adopted to persuade the inhabitants of the Plebiscite areas to vote for Poland".
replication rate The speed at which deoxyribonucleotides are incorporated into an elongating chain by DNA polymerases during DNA replication; or more generally the speed at which any chromosome, genome, cell, or organism makes a complete, independently functional copy of itself.
Sources: en.wikipedia.org
=== 8 June === Russia claimed to have shot down three Ukrainian drones targeting an air base near Mozdok, in the first such attack in North Ossetia-Alania since the war began. One person was killed in a Russian attack in Kherson Oblast. Another was killed in an airstrike in Kharkiv Oblast. The HUR claimed to have damaged two Russian Su-57 fighter jets for the first time using drones during a strike on the Akhtubinsk air base in Astrakhan Oblast. Drones also damaged the Russian tug boat Inzhener Smirnov and the barge Sectsia 179 in Taganrog Bay. A Ukrainian warplane struck a target in Russia using an air delivered weapon for the first time during an attack on a "command node" in Belgorod Oblast. The ISW assessed that Russia had resumed using the Crimean Bridge to transport fuel into Ukraine for the first time since it was suspended in March 2024 due to Ukrainian attacks.
Cytometry by time of flight, or CyTOF, is an application of mass cytometry used to quantify labeled targets on the surface and interior of single cells. CyTOF allows the quantification of multiple cellular components simultaneously using an ICP-MS detector. CyTOF takes advantage of immunolabeling to quantify proteins, carbohydrates or lipids in a cell. Targets are selected to answer a specific research question and are labeled with lanthanide metal tagged antibodies. Labeled cells are nebulized and mixed with heated argon gas to dry the cell containing particles. The sample-gas mixture is focused and ignited with an argon plasma torch. This breaks the cells into their individual atoms and creates an ion cloud. Abundant low weight ions generated from environmental air and biological molecules are removed using a quadrupole mass analyzer. The remaining heavy ions from the antibody tags are quantified by Time-of-flight mass spectrometry. Ion abundances correlate with the amount of target per cell and can be used to infer cellular qualities. Mass spectrometry's sensitivity to detect different ions allows measurements of upwards of 50 targets per cell while avoiding issues with spectral overlap seen when using fluorescent probes. However, this sensitivity also means trace heavy metal contamination is a concern. Using large numbers of probes creates new problems in analyzing the high dimensional data generated.
== Overdose == As with other GABAergic drugs, combination with other drugs that depress the respiratory system, such as alcohol, sedatives, and opioids, is risky. Overdose symptoms are similar to those of other GABAergics, including excessive sedation and unresponsiveness to stimuli, severe ataxia, amnesia, confusion, agitation, intoxication, and inappropriate (potentially violent) behavior. Severe overdoses may present with respiratory depression (and subsequent pulmonary aspiration), coma, and death. Carisoprodol is not detected on all toxicology tests, which may delay diagnosis of overdose. Overdose symptoms in combination with opiates are similar but are distinguished by the presentation of normal or pinpoint pupils, which are generally unresponsive to light. Carisoprodol (as with its metabolite meprobamate) is particularly dangerous in combination with alcohol. Flumazenil (the benzodiazepine antidote) is not effective in managing carisoprodol overdose as carisoprodol acts at the barbiturate binding site. Treatment mirrors that of barbiturate overdoses and is generally supportive, including the administration of mechanical respiration and pressors as indicated and, in rare cases, bemegride. Total amnesia of the experience is not uncommon following recovery. In 2014, actress Skye McCole Bartusiak died of an overdose due to the combined effects of carisoprodol, hydrocodone, and difluoroethane. In 1999, actress Dana Plato died after taking carisoprodol with the hydrocodone/paracetamol painkiller Lortab, in an overdose that was ruled a suicide.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.